Sunday, November 22, 2026
28.1 C
Bengaluru

Indian Hospitals and Private Equity: Healthy for Patients?

If healthcare is so lucrative that global private equity firms are willing to write cheques of Rs 13,000–14,000 crore for a single mid-sized Indian hospital chain, why is the Indian government still reluctant to invest at scale?

Public health expenditure in India remains stubbornly low — around 1.4–1.8 per cent of GDP in recent National Health Accounts estimates, far short of the National Health Policy 2017 target of 2.5 per cent by 2025. The Centre’s own allocation hovers near 0.26–0.28 per cent of GDP.

States carry the bulk of the burden, yet the combined public effort has never matched the rhetoric of “health as a right.” Fiscal constraints, competing demands (defence, infrastructure, subsidies), and the political economy of short-term welfare schemes over long-term capacity building explain part of the story. The deeper issue is that governments prefer to underwrite demand (through insurance schemes like Ayushman Bharat) rather than own and operate supply at the scale private capital is now willing to fund.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img